← Eichor
Study identifier: NCT06320431 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Condition: Acute Ischemic Stroke AIS · Stroke Acute · Stroke, Acute, Stroke Ischemic  ·  Sponsor: University of Calgary

PhasePhase 3
Planned participants4000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. This domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with acute ischemic stroke and are considered for intravenous thrombolysis. In addition, this domain also seeks to study standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) vs. no TNK upfront with rescue IA TNK if necessary (in those eligible for emergency EVT) and no TNK upfront in those who have taken DOACs during the preceding 48 hours. This domain therefore seeks to generate more robust randomized evidence to guide clinicians in their decisions over the balance of risks and treatment with intravenous thrombolysis with tenecteplase wherever such evidence is currently insufficient. This domain will currently evaluate four research questions in relation to the use of IVT with tenecteplase: 1. In patients with recent (48 hours) in…

This description comes directly from the study's public registry record.

Talk to the study team

Bijoy K Menon, MD  ·  4039448107  ·  bkmmenon@ucalgary.ca

Craig Anderson, MD  ·  4039448107  ·  canderson@georgeinstitute.org.au

Always discuss trial participation with your own doctor first.

Locations (24)

The George Institute for Global HealthSydney, Barangaroo, AustraliaNot Yet Recruiting
Royal Prince Alfred HospitalSydney, New South Wales, AustraliaRecruiting
Monash University (Box Hill)Melbourne, Victoria, AustraliaRecruiting
University of CalgaryCalgary, Alberta, CanadaRecruiting
Medicine Hat Regional HospitalMedicine Hat, Alberta, CanadaNot Yet Recruiting
Red Deer Regional HospitalRed Deer, Alberta, CanadaNot Yet Recruiting
University of AlbertaEdmonton, A, CanadaRecruiting
Kelowna Regional HospitalKelowna, British Columbia, CanadaNot Yet Recruiting
Royal Columbian HospitalNew Westminster, British Columbia, CanadaNot Yet Recruiting
University of British ColumbiaVancouver, British Columbia, CanadaRecruiting
Brandon Regional HospitalBrandon, Manitoba, CanadaNot Yet Recruiting
University of Manitoba - Winnipeg Health Science CentreWinnipeg, Manitoba, CanadaRecruiting

+ 12 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06320431